Connect with us

Hi, what are you looking for?

Economy

AstraZeneca COVID-19 vaccine 76% effective in new analysis of US trial

AstraZeneca said its coronavirus disease 2019 (COVID-19) vaccine was 76% effective at preventing symptomatic illness in a new analysis of its major US trial—a tad lower than the level announced earlier this week in a report that was criticized for using outdated information.

US health officials had publicly rebuked the drugmaker for not using the most up-to-date information when it published an interim analysis on Monday that said the vaccine was 79% effective.

The latest data was based on 190 infections among more than 32,400 participants in the United States, Chile, and Peru. The earlier interim data was based on 141 infections through Feb. 17.

“The primary analysis is consistent with our previously released interim analysis, and confirms that our COVID-19 vaccine is highly effective in adults,” Mene Pangalos, executive vice-president of BioPharmaceuticals R&D at AstraZeneca said in a statement.

AstraZeneca said it plans to seek US emergency use authorization in the coming weeks and the latest data has been presented to the independent trial oversight committee, the Data Safety Monitoring Board.

AstraZeneca reiterated on Thursday that the shot, developed with Oxford University, was 100% effective against severe or critical forms of the disease. It also said the vaccine showed 85% efficacy in adults 65 years and older.

“A lot of us were waiting for this large, well-constructed, and reported Phase III study,” said Paul Griffin, a professor at the University of Queensland.

“This appears to be a very effective vaccine with no safety concerns. Hopefully, this should now give people the confidence that this vaccine is the right one to continue to use moving forward,” he said, adding that he and his parents have taken the vaccine.

The updated 76% efficacy rate compares with rates of about 95% for vaccines from Pfizer/BioNTech and Moderna.

The AstraZeneca vaccine is, however, seen as crucial in tackling the spread of COVID-19 across the globe, not just due to limited vaccine supply but also because it is easier and cheaper to transport than rival shots. It has been granted conditional marketing or emergency use authorization in more than 70 countries.

 

The highly unusual rebuke from US health authorities had marked a fresh setback for the vaccine that was once hailed as a milestone in the fight against the COVID-19 pandemic, but has been dogged by questions over its effectiveness and possible side-effects.

The shot has faced questions since late last year when the drugmaker and Oxford University published data from an earlier trial with two different efficacy readings as a result of a dosing error.

Then this month, more than a dozen countries temporarily suspended giving out the vaccine after reports linked it to a rare blood clotting disorder in a very small number of people.

The European Union’s drug regulator said last week the vaccine was clearly safe, but Europeans remain skeptical about its safety. — Rocky Swift/Reuters

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest

Investing

Lloyd’s of London could leave its iconic City of London headquarters after four decades in one of the most consequential signs yet of how...

Investing

As we enter a new year, I want to talk about the importance of balance, perspective, support and productivity and I’m here to make...

Investing

London-based edtech company MyTutor has acquired Fire Tech, a training platform that teaches children technology skills such as coding. The acquisition will see MyTutor...

Investing

British autonomous vehicle startup Wayve has raised $200m (£147m) in a funding round backed by Microsoft and Virgin. The London-based firm will use the...

Investing

London-based contract automation platform Juro has raised $23m (£16.9m) in a Series B funding round. The funding was led by Eight Roads, a global...

Investing

To sustain business growth, it’s crucial to create key business opportunities. Don’t be so busy in your day-to-day that you miss them … Faced...

You May Also Like

Investing

Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...

Economy

Ivermectin, an existing drug against parasites including head lice, has had a checkered history when it comes to treating COVID-19. The bulk of studies...

Investing

Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered throughout...

Investing

As a traditionally rigid insurance industry becomes bogged down by antiquated processes and operations, a handful of industry leaders are seeking to shake things...

Disclaimer: SmartRetirementReport.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.